




Searching News Database: oral mucositis
HSMN NewsFeed - 18 Sep 2020
BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
HSMN NewsFeed - 15 May 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
HSMN NewsFeed - 16 Sep 2019
Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
HSMN NewsFeed - 8 Jul 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
HSMN NewsFeed - 24 Jul 2018
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
Soligenix Announces Appointment of Mark Pearson to its Board of Directors
HSMN NewsFeed - 6 Mar 2017
Izun Pharmaceuticals Announces Approval of Curasite(TM) Hydrogel Wound Care Product by FDA
Izun Pharmaceuticals Announces Approval of Curasite(TM) Hydrogel Wound Care Product by FDA
HSMN NewsFeed - 1 Dec 2016
Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid(R) Gel
Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid(R) Gel
HSMN NewsFeed - 23 Jan 2016
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
HSMN NewsFeed - 23 Sep 2014
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
HSMN NewsFeed - 8 Sep 2014
AMAG Pharmaceuticals Announces Appointment of John A. Fallon, M.D. to Board of Directors
AMAG Pharmaceuticals Announces Appointment of John A. Fallon, M.D. to Board of Directors
HSMN NewsFeed - 12 Aug 2014
AMAG Pharmaceuticals Appoints Robert Blood as Vice President of Legal Affairs and Chief Compliance Officer
AMAG Pharmaceuticals Appoints Robert Blood as Vice President of Legal Affairs and Chief Compliance Officer
HSMN NewsFeed - 7 Jan 2014
AMAG Pharmaceuticals Appoints Elizabeth Bolgiano as Senior Vice President of Human Resources
AMAG Pharmaceuticals Appoints Elizabeth Bolgiano as Senior Vice President of Human Resources
HSMN NewsFeed - 20 Dec 2013
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
HSMN NewsFeed - 21 Oct 2013
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
Soligenix Announces Appointment of Marco Maria Brughera to its Board of Directors
HSMN NewsFeed - 3 Oct 2013
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
Soligenix Appoints Oreola Donini, PhD, as Vice President of Preclinical Research and Development
HSMN NewsFeed - 16 Sep 2013
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
HSMN NewsFeed - 24 Jun 2013
AMAG Pharmaceuticals Appoints Steven Caffe, M.D. as Chief Development and Regulatory Officer
AMAG Pharmaceuticals Appoints Steven Caffe, M.D. as Chief Development and Regulatory Officer
HSMN NewsFeed - 22 Oct 2012
DARA BioSciences Launches Soltamox(R), First and Only Liquid Version of Tamoxifen Citrate
DARA BioSciences Launches Soltamox(R), First and Only Liquid Version of Tamoxifen Citrate
HSMN NewsFeed - 18 Nov 2011
EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE(TM) for Treatment of Acute Lymphoblastic Leukemia
EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE(TM) for Treatment of Acute Lymphoblastic Leukemia
HSMN NewsFeed - 29 Jul 2009
Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America
HSMN NewsFeed - 27 Jul 2009
Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
HSMN NewsFeed - 23 Jul 2009
MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
HSMN NewsFeed - 20 Apr 2009
SpePharm Announces the European Launches of Two New Products: MuGard and Xerotin
SpePharm Announces the European Launches of Two New Products: MuGard and Xerotin
HSMN NewsFeed - 19 Feb 2009
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
HSMN NewsFeed - 13 Mar 2008
Hawthorn Pharmaceuticals, Inc. Receives FDA Approval on Granisol(TM) Oral Solution
Hawthorn Pharmaceuticals, Inc. Receives FDA Approval on Granisol(TM) Oral Solution
HSMN NewsFeed - 3 Mar 2008
Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform
Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform
HSMN NewsFeed - 4 Feb 2008
EKR Therapeutics and PDL BioPharma Sign Asset Purchase Agreement for Cardiovascular Products
EKR Therapeutics and PDL BioPharma Sign Asset Purchase Agreement for Cardiovascular Products
HSMN NewsFeed - 19 Sep 2007
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
HSMN NewsFeed - 12 Sep 2007
Innocoll Enters Into Collaboration With TGR Biosciences for Development of a Novel Wound Healing Product
Innocoll Enters Into Collaboration With TGR Biosciences for Development of a Novel Wound Healing Product
HSMN NewsFeed - 15 Aug 2007
EKR Therapeutics Raises Over $13 Million in a Series C Financing Round From New and Existing Investors
EKR Therapeutics Raises Over $13 Million in a Series C Financing Round From New and Existing Investors
HSMN NewsFeed - 11 Jun 2007
Cytogen Announces New Sales and Marketing Leadership with the Appointment of Stephen A. Ross
Cytogen Announces New Sales and Marketing Leadership with the Appointment of Stephen A. Ross
HSMN NewsFeed - 10 May 2007
ProCertus BioPharm, Inc. Closes $2.3 Million Series A Financing Led by Venture Investors LLC
ProCertus BioPharm, Inc. Closes $2.3 Million Series A Financing Led by Venture Investors LLC
HSMN NewsFeed - 21 Feb 2007
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
HSMN NewsFeed - 8 Feb 2007
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
Access Pharmaceuticals Appoints Esteban Cvitkovic, M.D. as Director and Vice Chairman (Europe)
HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
HSMN NewsFeed - 18 Dec 2006
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
HSMN NewsFeed - 13 Dec 2006
Access Pharmaceuticals Receives MuGard(TM) Marketing Clearance From the FDA
Access Pharmaceuticals Receives MuGard(TM) Marketing Clearance From the FDA
HSMN NewsFeed - 12 Oct 2006
MGI PHARMA Receives Approvable Letter for Saforis(TM) (Glutamine) Powder in UpTec(TM) for Oral Suspension
MGI PHARMA Receives Approvable Letter for Saforis(TM) (Glutamine) Powder in UpTec(TM) for Oral Suspension
HSMN NewsFeed - 12 Oct 2006
EKR Therapeutics Acquires Exclusive License for Gelclair(R) from Helsinn Healthcare SA
EKR Therapeutics Acquires Exclusive License for Gelclair(R) from Helsinn Healthcare SA
Additional items found! 77

Members Archive contains
77 additional stories matching:
oral mucositis
(Password required)
oral mucositis
(Password required)